These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10855459)

  • 21. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia].
    Gavrilova SI; Kolykhalov IV; Mikhaylova NM; Ponomareva EV; Fedorova YB; Medvedev VE; Frolova VI; Gushanskaya EV; Litvinenko IV; Emelin AY; Lobzin VY; Kashin AV; Tanashyan MM; Kachanova MV; Knyazev AV; Gonik MI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):69-77. PubMed ID: 38465812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
    Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
    Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
    Talwalker S
    J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
    Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
    Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of disease progression and dropout for Alzheimer's disease.
    William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of xantinolnicotinate in patients with dementia.
    Kanowski S; Fischhof PK; Grobe-Einsler R; Wagner G; Litschauer G
    Pharmacopsychiatry; 1990 May; 23(3):118-24. PubMed ID: 2197635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
    Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
    J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naftidrofuryl in the treatment of vascular dementia.
    Möller HJ; Hartmann A; Kessler C; Rainer M; Brown T; Gamand S; Lehert P
    Eur Arch Psychiatry Clin Neurosci; 2001 Dec; 251(6):247-54. PubMed ID: 11881837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naftidrofuryl in the treatment of mild senile dementia. A double-blind study.
    Grossmann WM; Standl A; May U; van Laak HH; Hirche H
    Pharmacopsychiatry; 1990 Nov; 23(6):265-73. PubMed ID: 2284328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.
    Le Bars PL; Velasco FM; Ferguson JM; Dessain EC; Kieser M; Hoerr R
    Neuropsychobiology; 2002; 45(1):19-26. PubMed ID: 11803237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.